Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib dose titration in advanced gastric cancer
NCT02764268Completed
- Sponsor
- Hengrui
- Start
- Nov 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Rivoceranib in gastric cancer (GC), sponsored by Hengrui. Primary endpoint: Number of Participants With Dose Interruptions at 15 months. Started Nov 2016; status: completed.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02764268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02764268.